肌醇 1,4,5-三磷酸受体相互作用蛋白样 1 (ITPR​​IPL1) 是一种位于膜中的单通道 I 型膜蛋白，充当 CD3ε 的抑制性配体。最近的研究表明，其表达可抑制T细胞活化并促进肿瘤免疫逃避。尽管越来越多的证据表明 ITPRIPL1 在肿瘤生长中发挥着重要作用，但迄今为止尚未对 ITPRIPL1 进行系统的泛癌分析。本研究利用癌症基因组图谱、基因型组织表达和人类蛋白质图谱整理的数据集来研究 ITPRIPL1 表达与 33 种癌症类型的临床结果、免疫浸润和药物敏感性之间的关系。我们采用单变量Cox回归、生存分析、ROC曲线分析等多种方法评估其在泛癌中的预后价值，并探讨ITPRIPL1与肿瘤突变负荷（TMB）、肿瘤微卫星不稳定性（MSI）、CNV、 DNA甲基化、免疫相关基因、免疫细胞浸润和药物敏感性揭示其免疫作用。 ITPRIPL1 基因的 mRNA 表达水平在多种类型的癌症中存在显着差异，并且在乳腺癌中显着降低。相反，ITPRIPL1 高表达与 BRCA 患者更好的预后相关。此外，ITPRIPL1 的表达与各种癌症中肿瘤浸润免疫细胞和免疫检查点基因的存在高度相关。此外，ITPRIPL1 表达与 6 种癌症类型中的 TMB 相关，以及与 13 种癌症类型中的 MSI 相关。 ITPRIPL1 的高表达可作为某些癌症类型的保护因素，与 BRCA 患者的较长总体生存期相关。我们的研究进一步证实ITPRIPL1参与调节免疫浸润并影响泛癌患者的预后。这些发现强调了 ITPRIPL1 作为人类癌症治疗靶点的巨大潜力。版权所有 © 2024 Duan、Tian、Li、Liu 和 Xu。

Inositol 1,4,5-Trisphosphate Receptor-Interacting Protein-Like 1 (ITPRIPL1), a single-pass type I membrane protein located in the membrane, functions as an inhibitory ligand of CD3ε. Recent studies have shown that its expression suppresses T cells activation and promote tumor immune evasion. Despite increasing evidence suggesting that ITPRIPL1 plays a significant role in tumor growth, no systematic pan-cancer analysis of ITPRIPL1 has been conducted to date. This study utilized datasets curated from The Cancer Genome Atlas, Genotype Tissue-Expression, and Human Protein Atlas to investigate the relationship between ITPRIPL1 expression and clinical outcomes, immune infiltration, and drug sensitivity across 33 cancer types. We employed multiple methods to assess its prognostic value in pan-cancer, such as univariate Cox regression, survival analysis, and ROC curve analysis and explored the relationship between ITPRIPL1 and tumor mutation burden (TMB), tumor microsatellite instability (MSI), CNV, DNA methylation, immune-related genes, immune cell infiltration, and drug sensitivity to reveal its immunological role. The mRNA expression levels of the ITPRIPL1 gene vary significantly across multiple types of cancer and significantly reduced in breast cancer. Conversely, high ITPRIPL1 expression was associated with a better prognosis in BRCA. Furthermore, the expression of ITPRIPL1 highly correlates with the presence of tumor-infiltrating immune cells and immune checkpoint genes across various types of cancers. Additionally, ITPRIPL1 expression was associated with TMB in 6 cancer types and with MSI in 13 cancer types. High expression of ITPRIPL1 serves as a protective factor in certain cancer types, correlating with longer overall survival in BRCA. Our study further confirms that ITPRIPL1 participates in regulating immune infiltration and affecting the prognosis of patients in pan-cancer. These findings underscore the promising potential of ITPRIPL1 as a therapeutic target for human cancer.Copyright © 2024 Duan, Tian, Li, Liu and Xu.